Pharos Biologicals is developing vaccines for the prevention of flavivirus and influenza infections, using Johns Hopkins University School of Medicine's proprietary lysosome-associated membrane protein (LAMP) DNA vaccine technology and other nano technologies. Preclinical research for Zika virus infection is ongoing in the US, with early research underway for dengue and influenza infections.
The LAMP technology utilises normal cellular mechanisms to enhance the immune response to the vaccine, which is comprised of antigen protein sequences are encoded as an antigen/LAMP chimera construct. The LAMP DNA vaccine is not a live virus vaccine, has a more rapid development time line, delivers the pathogen antigen directly to cell proteins that bring about immunological responses, and is highly stable.
Viral vaccines program is available for licensing (Pharos Biologicals website, May 2016).
As at June 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection in USA, research development in Dengue in USA, research development in Influenza-virus-infections in USA.
In May 2016, Pharos Biologicals received exclusive worldwide license for a patented Lysosome-Associated Membrane Protein (LAMP) DNA vaccine technology and other nanotechnologies from Johns Hopkins University School of Medicine. Financial details of the deal were not disclosed  .
Key Development Milestones
Pharos Biologicals is planning to initiate a phase I clinical trial in patients with Zika virus infection, by the end of 2016   .